BidaskClub upgraded shares of Assembly Biosciences (NASDAQ:ASMB) from a strong sell rating to a sell rating in a research note issued to investors on Wednesday morning, BidAskClub reports.

Other equities research analysts have also recently issued reports about the company. ValuEngine raised Assembly Biosciences from a hold rating to a buy rating in a research note on Thursday, August 8th. Chardan Capital reaffirmed a hold rating and set a $30.00 price objective on shares of Assembly Biosciences in a research note on Wednesday, August 7th. Zacks Investment Research raised Assembly Biosciences from a hold rating to a buy rating and set a $13.00 price objective for the company in a research note on Tuesday, September 17th. Finally, William Blair reaffirmed a buy rating on shares of Assembly Biosciences in a research note on Tuesday, July 16th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of Buy and an average target price of $32.50.

NASDAQ ASMB opened at $14.11 on Wednesday. The stock has a fifty day moving average of $12.21 and a 200-day moving average of $15.06. Assembly Biosciences has a 52 week low of $10.58 and a 52 week high of $38.42. The company has a debt-to-equity ratio of 0.06, a current ratio of 9.20 and a quick ratio of 9.20.

Assembly Biosciences (NASDAQ:ASMB) last released its earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.72) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.13) by $0.41. The company had revenue of $3.08 million during the quarter, compared to analysts’ expectations of $3.90 million. Assembly Biosciences had a negative return on equity of 46.33% and a negative net margin of 622.25%. On average, sell-side analysts anticipate that Assembly Biosciences will post -3.72 earnings per share for the current fiscal year.

Several institutional investors have recently made changes to their positions in ASMB. Nuveen Asset Management LLC acquired a new stake in shares of Assembly Biosciences during the second quarter worth $3,681,000. Citadel Advisors LLC grew its stake in shares of Assembly Biosciences by 90.0% during the second quarter. Citadel Advisors LLC now owns 450,315 shares of the biopharmaceutical company’s stock worth $6,075,000 after purchasing an additional 213,363 shares during the period. Vanguard Group Inc. grew its stake in shares of Assembly Biosciences by 13.6% during the second quarter. Vanguard Group Inc. now owns 1,226,953 shares of the biopharmaceutical company’s stock worth $16,552,000 after purchasing an additional 146,452 shares during the period. Rock Springs Capital Management LP grew its stake in shares of Assembly Biosciences by 24.4% during the second quarter. Rock Springs Capital Management LP now owns 560,000 shares of the biopharmaceutical company’s stock worth $7,554,000 after purchasing an additional 110,000 shares during the period. Finally, Renaissance Technologies LLC grew its stake in shares of Assembly Biosciences by 338.5% during the second quarter. Renaissance Technologies LLC now owns 133,300 shares of the biopharmaceutical company’s stock worth $1,798,000 after purchasing an additional 102,900 shares during the period. 81.94% of the stock is owned by institutional investors and hedge funds.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.

Featured Article: What is the Beige Book?

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.